Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine, including promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more non-ionic surfactants and at least one amino acid and/or one polyol prior to administration to an animal such as a mammal.
Type:
Grant
Filed:
June 26, 2002
Date of Patent:
October 17, 2006
Assignee:
Baxter International Inc.
Inventors:
Jianwei Yu, Pui-Ho Yuen, Virginia Paulate
Abstract: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.
Type:
Grant
Filed:
October 11, 2002
Date of Patent:
September 26, 2006
Assignee:
Baxter International Inc.
Inventors:
James E. Kipp, Mark J. Doty, Christine L. Rebbeck, Sean Brynjelsen, Jamie Teresa Konkel
Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of 400 nm to 2 microns.
Type:
Grant
Filed:
June 5, 2001
Date of Patent:
May 2, 2006
Assignee:
Baxter International Inc.
Inventors:
James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck
Abstract: The present invention is directed to a novel process for inserting a cannula, such as a hypodermic needle, into a hub member by roughening a first portion of the cannula while leaving a second portion substantially smooth such that the first portion forms an interference fit and the second portion a line-to-line fit with the hub bore. In the absence of an adhesive, the second portion is passed through the hub bore followed by the first portion. The first portion is forced into the hub bore to provide an adhesive-free interference fit that is capable of resisting puncturing forces during normal use.
Abstract: The present invention provides for measuring a particle size distribution of a population of particles using a light scattering particle sizing instrument having a plurality of selectable imaginary component values of the refractive index. The particles each having a particle size and the process includes the steps of: (i) providing a population of the particles, wherein the particles have a refractive index; (ii) determining a real component of the refractive index of the particles using the Becke Line Method; (iii) determining an imaginary component of the refractive index of the particles; and (iv) determining the particle size distribution of the particles by the light scattering particle sizing instrument wherein the particle size distribution is determined using the real component of the refractive index measured in step (ii) and the imaginary component of the refractive index determined in step (iii).
Type:
Grant
Filed:
April 21, 2003
Date of Patent:
March 7, 2006
Assignee:
Baxter International Inc.
Inventors:
Joseph Chung Tak Wong, Damian Neuberger
Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more cyclodextrin derivatives, and if desired, one or more non-ionic surfactants such as the partial esters of sorbitol and the polyoxyethylene oxides of long chain fatty acids such as the polysorbates.
Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound; and (iii) seeding the first solution or the second solvent or the pre-suspension.
Type:
Grant
Filed:
October 19, 2001
Date of Patent:
December 20, 2005
Assignee:
Baxter International Inc.
Inventors:
Jane Werling, James E. Kipp, Rajaram Sriram, Mark J. Doty
Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of less than about 2 ?m.
Type:
Grant
Filed:
September 17, 2001
Date of Patent:
October 4, 2005
Assignee:
Baxter International Inc.
Inventors:
James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck, Sean Brynjelsen
Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound; and (iii) seeding the first solution or the second solvent or the pre-suspension.
Type:
Grant
Filed:
December 12, 2001
Date of Patent:
April 26, 2005
Assignee:
Baxter International Inc.
Inventors:
James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Jane Werling, Christine L. Rebbeck, Sean Brynjelsen
Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of 400 nm to 2 microns.
Type:
Grant
Filed:
June 5, 2001
Date of Patent:
March 22, 2005
Assignee:
Baxter International Inc.
Inventors:
James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck
Abstract: Systems and methods treat plasma carrying contaminants and cellular matter that are capable of entraining contaminants. The systems and methods separate cellular matter from the plasma by filtration, thereby removing contaminants entrained within the cellular matter. The system and methods add to the plasma a photoactive material. The systems and methods emit radiation at a selected wavelength into the plasma to activate the photoactive material and thereby eradicate the contaminant that is free of entrainment by cellular matter.
Type:
Grant
Filed:
October 13, 2000
Date of Patent:
February 15, 2005
Assignee:
Baxter International Inc.
Inventors:
Robert E. Herman, John Chapman, Chong-Son Sun, Jean M. Mathias, Veronique Mayaudon, Serge de Gheldere, Daniel F. Bischof
Abstract: The present invention relates to a process for preparing submicron sized nanoparticles of a poorly water soluble compound by lyophilizing a dispersion or microdispersion of a multiphase system having an organic phase and an aqueous phase, the organic phase having the poorly water soluble organic compound therein. The method is preferably used to prepare nanoparticles of a poorly water soluble, pharmaceutically active compound suitable for in vivo delivery, particularly by parenteral routes.
Type:
Grant
Filed:
June 26, 2002
Date of Patent:
December 28, 2004
Assignee:
Baxter International Inc.
Inventors:
Sean Brynjelsen, Mark Doty, James E. Kipp, Nailesh Jayswal, Krishnaswamy Narayanan
Abstract: The present invention is directed to a novel process for inserting a cannula into a hub member. The process uses an interference or frictional fit between the bore of the hub member and the cannula's exterior surface. In this manner, adhesives are not required in the assembly of the two components.
Abstract: An apparatus for irradiating materials is disclosed. The apparatus includes a housing defining a chamber and a pair of light sources positioned on opposite sides of the chamber. The housing includes a pair of housing sections moveable in hinged relation between open and closed positions. A manually removable tray within the housing to define a support suface for a flexible container in the chamber is also provided.
Abstract: Systems and methods treat plasma carrying contaminants and leukocytes that are capable of entraining contaminants. The systems and methods separate leukocytes from the plasma by filtration, thereby removing contaminants entrained within leukocytes. The systems and methods also add to the plasma a photoactive material and emit radiation at a selected wavelength into the plasma to activate the photoactive material and thereby eradicate the contaminant that is free of entrainment by leukocytes.
Type:
Grant
Filed:
May 5, 1998
Date of Patent:
February 24, 2004
Assignee:
Baxter International Inc.
Inventors:
Chong-Son Sun, John Chapman, Daniel F Bischof, Robert E Herman
Abstract: Needle protectors for retaining needles are disclosed. The needle protector includes a housing with an opening at each of a proximal and distal end. The needle protector may include a portion that is depressible to a substantially fixed position over the needle retracted within the housing.
Type:
Grant
Filed:
November 17, 1999
Date of Patent:
October 14, 2003
Assignee:
Baxter International Inc.
Inventors:
Jean-Marie Mathias, Philippe Van Heems, Gianni Di Stefani, Thomas Walter Coneys
Abstract: Apparatus for withdrawing whole blood from a donor, separating the whole blood to obtain a target cell population and returning a selected one of either the target cell population or at least a portion of the whole blood remainder to the donor or patient. A disposable separation inset for use in association with a rotatable separation device of the apparatus may also be provided. The disposable inset may include a chamber for receiving a cell suspension that includes the target cell, a receptacle for containing particles having a binding site for selectively binding to the target cell and a means for introducing the particles into the chamber.
Type:
Grant
Filed:
February 16, 2001
Date of Patent:
July 22, 2003
Assignee:
Baxter International Inc.
Inventors:
Richard Giesler, John R. Chapman, Dale R. Ellis, Daniel F. Bischof